Additive effect of the combination of glatiramer acetate and minocycline in a model of MS

Journal of Neuroimmunology

Volumn 158, Issue 1-2, 2005, Pages 213-221

  Giuliani, Fabrizio ^a   Metz, Luanne M ^a   Wilson, Tammy ^a   Fan, Yan ^a   Bar Or, Amit ^b   Wee Yong, V ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

EAE; Glatiramer acetate; Minocycline; Multiple sclerosis

Indexed keywords

DRUG ADDITIVE; GLATIRAMER; MINOCYCLINE;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFECT; DRUG SCREENING; MOUSE; MULTIPLE SCLEROSIS; NERVE FIBER; NONHUMAN; PRIORITY JOURNAL;

ANALYSIS OF VARIANCE; ANIMALS; ANTI-BACTERIAL AGENTS; CYTOKINES; DEMYELINATING DISEASES; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; LYMPH NODES; MICE; MICE, INBRED C57BL; MINOCYCLINE; MULTIPLE SCLEROSIS; MYELIN-ASSOCIATED GLYCOPROTEIN; PEPTIDES; SILVER STAINING; SPLEEN; TIME FACTORS;

EID: 10344257516     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2004.09.006     Document Type: Article

References (41)

1. R. Aharoni, D. Teitelbaum, O. Leitner, A. Meshorer, M. Sela, and R. Arnon Specific Th2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer 1 Proc. Natl. Acad. Sci. U. S. A. 97 2000 11472 11477
2. E. Akin, L.C. Miller, and L.B. Tucker Minocycline-induced lupus in adolescents Pediatrics 101 1998 926
3. D. Andes, and W.A. Craig Animal model pharmacokinetics and pharmacodynamics: a critical review Int. J. Antimicrob. Agents 19 2003 261 268
4. K. Biernacki, A. Prat, M. Blain, and J.P. Antel Regulation of Th1 and Th2 lymphocyte migration by human adult brain endothelial cells J. Neuropathol. Exp. Neurol. 60 2001 1127 1136
5. S.A. Brod, J.W. Lindsey, and J.S. Wolinsky Combination therapy with glatiramer acetate (copolymer-1) and a type I interferon (IFN-alpha) does not improve experimental autoimmune encephalomyelitis Ann. Neurol. 47 2000 127 131
6. V. Brundula, N.B. Rewcastle, L.M. Metz, C.C. Bernard, and V.W. Yong Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis Brain 125 2002 1297 1308
7. P.A. Calabresi, J.L. Wilterdink, J.M. Rogg, P. Mills, A. Webb, and K.A. Whartenby An open-label trial of combination therapy with interferon beta-1a and oral methotrexate in MS Neurology 58 2002 314 317
8. M. Chen, V.O. Ona, M. Li, R.J. Ferrante, K.B. Fink, and S. Zhu Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease Nat. Med. 6 2000 797 801
9. M. Colovic, and S. Caccia Liquid chromatographic determination of minocycline in brain-to-plasma distribution studies in the rat J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 791 2003 337 343
10. Y. Du, Z. Ma, S. Lin, R.C. Dodel, F. Gao, and K.R. Bales Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease Proc. Natl. Acad. Sci. U. S. A. 98 2001 14669 14674
11. O. Elkayam, M. Yaron, and D. Caspi Minocycline-induced autoimmune syndromes: an overview Semin. Arthritis Rheum. 28 1999 392 397
12. S.C. Fagan, D.J. Edwards, and C.V. Borlongan Optimal delivery of minocycline to the brain: implication for human studies of acute neuroprotection Exp. Neurol. 186 2004 248 251
13. B. Ferguson, M.K. Matyszak, M.M. Esiri, and V.H. Perry Axonal damage in acute multiple sclerosis lesions Brain 120 1997 393 399
14. A. Gough, S. Chapman, K. Wagstaff, P. Emery, and E. Elias Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome BMJ 312 1996 169 172
15. T. Katakai, T. Hara, M. Sugai, H. Gonda, Y. Nambu, and E. Matsuda Chemokine-independent preference for T-helper-1 cells in transendothelial migration J. Biol. Chem. 277 2002 50948 50958
16. J. Kipnis, and M. Schwartz Dual action of glatiramer acetate (Cop-1) in the treatment of CNS autoimmune and neurodegenerative disorders Trends Mol. Med. 8 2002 319 323
17. J. Kipnis, E. Yoles, Z. Porat, A. Cohen, F. Mor, and M. Sela T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies Proc. Natl. Acad. Sci. U. S. A. 97 2000 7446 7451
18. F. Lublin, M. Baier, and G. Cutter Results of the extension of a trial to assess the longer term safety of combining interferon beta-1a and glatiramer acetate Neurology 58 Suppl. 3 2003 A85
19. L.M. Metz, Y. Zhang, and M. Yeung Minocycline reduces gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis Ann. Neurol. 55 2004 756
20. S. Nessler, R. Dodel, A. Bittner, S. Reuss, Y. Du, and B. Hemmer Effect of minocycline in experimental autoimmune encephalomyelitis Ann. Neurol. 52 2002 689 690
21. O. Neuhaus, C. Farina, H. Wekerle, and R. Hohlfeld Mechanisms of action of glatiramer acetate in multiple sclerosis Neurology 56 2001 702 708
22. J.R. O'Dell Is there a role for antibiotics in the treatment of patients with rheumatoid arthritis? Drugs 57 1999 279 282
23. N. Popovic, A. Schubart, B.D. Goetz, S.C. Zhang, C. Linington, and I.D. Duncan Inhibition of autoimmune encephalomyelitis by a tetracycline Ann. Neurol. 51 2002 215 223
24. S. Saivin, and G. Houin Clinical pharmacokinetics of doxycycline and minocycline Clin. Pharmacokinet. 15 1988 355 366
25. H. Schori, J. Kipnis, E. Yoles, E. WoldeMussie, G. Ruiz, and L.A. Wheeler Vaccination for protection of retinal ganglion cells against death from glutamate cytotoxicity and ocular hypertension: implications for glaucoma Proc. Natl. Acad. Sci. U. S. A. 98 2001 3398 3403
26. M. Sela, and D. Teitelbaum Glatiramer acetate in the treatment of multiple sclerosis Expert Opin. Pharmacother. 2 2001 1149 1165
27. D.C. Seukeran, E.A. Eady, and W.J. Cunliffe Benefit-risk assessment of acne therapies Lancet 349 1997 1251 1252
28. L.E. Shapiro, S.R. Knowles, and N.H. Shear Comparative safety of tetracycline, minocycline, and doxycycline Arch. Dermatol. 133 1997 1224 1230
29. J.M. Soos, O. Stuve, S. Youssef, M. Bravo, H.M. Johnson, and H.L. Weiner Cutting edge: oral type I IFN-tau promotes a Th2 bias and enhances suppression of autoimmune encephalomyelitis by oral glatiramer acetate J. Immunol. 169 2002 2231 2235
30. M.C. Sturkenboom, C.R. Meier, H. Jick, and B.H. Stricker Minocycline and lupus like syndrome in acne patients Arch. Intern. Med. 159 1999 493 497
31. T. Tikka, B.L. Fiebich, G. Goldsteins, R. Keinanen, and J. Koistinaho Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia J. Neurosci. 21 2001 2580 2588
32. B.D. Trapp, J. Peterson, R.M. Ransohoff, R. Rudick, S. Mork, and L. Bo Axonal transection in the lesions of multiple sclerosis N. Engl. J. Med. 338 1998 278 285
33. J.E. Wells, R.J. Hurlbert, M.G. Fehlings, and V.W. Yong Neuroprotection by minocycline facilitates significant recovery from spinal cord injury in mice Brain 126 2003 1628 1637
34. D.C. Wu, V. Jackson-Lewis, M. Vila, K. Tieu, P. Teismann, and C. Vadseth Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine mouse model of Parkinson disease J. Neurosci. 22 2002 1763 1771
35. L. Xu, S.C. Fagan, and J.L. Waller Low dose intravenous minocycline is neuroprotective after middle cerebral artery occlusion-reperfusion in rats BMC Neurol. 4 2004 7
36. V.W. Yong Differential mechanisms of action of interferon-beta and glatiramer acetate in MS Neurology 59 2002 802 808
37. V.W. Yong, C. Power, P. Forsyth, and D.R. Edwards Metalloproteinases in biology and pathology of the nervous system Nat. Rev., Neurosci. 2 2001 502 511
38. Yong, V.W., Wells, J., Giuliani, F., Casha, S., Power, C., Metz, L.M. The promise of minocycline in neurology. Revised for Lancet Neurology
39. J. Yrjanheikki, R. Keinanen, M. Pellikka, T. Hokfelt, and J. Koistinaho Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia Proc. Natl. Acad. Sci. U. S. A. 95 1998 15769 15774
40. J. Yrjanheikki, T. Tikka, R. Keinanen, G. Goldsteins, P.H. Chan, and J. Koistinaho A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window Proc. Natl. Acad. Sci. U. S. A. 96 1999 13496 13500
41. S. Zhu, I.G. Stavrovskaya, M. Drozda, B.Y. Kim, V. Ona, and M. Li Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice Nature 417 2002 74 78